
|Videos|February 17, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Author(s)Jonathan R. Strosberg, MD
The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Advertisement
Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Articles in this issue
over 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancerover 10 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCover 10 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCover 10 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCover 10 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRCAdvertisement
Related to this article

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5

